Skip to main content
TipRanks
Go Ultimate75% OFF

Bristol-Myers Squibb (BMY) AI Stock Analysis

12,195 Followers
BMY

Bristol-Myers Squibb

(NYSE:BMY)

Select Model
Rating:69Neutral
Price Target:$67.00▲(6.47% Upside)
Action:reiterated
Date:10/30/26

The score is driven primarily by solid financial performance (strong current margins and cash generation, tempered by leverage and earnings/FCF volatility) and a constructive earnings update (raised guidance and strong growth-portfolio/pipeline momentum despite Eliquis LOE risk). Valuation is supportive due to a moderate P/E and high dividend yield, while technical indicators are neutral-to-mixed and do not add strong momentum support.

Positive Factors
Diversified growth portfolioA broad set of commercially meaningful medicines reduces reliance on any single product and supports more durable revenue expansion. The portfolio’s double-digit growth and multiple billion-dollar contributors provide a stronger base for absorbing individual product declines while funding continued innovation.
Negative Factors
Eliquis exclusivity lossEliquis is a major franchise, so the expected post-exclusivity decline creates a material revenue gap that the newer portfolio must replace. Even with continued U.S. growth, this transition can pressure earnings visibility and increase dependence on successful launches and pipeline execution.

Bristol-Myers Squibb Key Performance Indicators (KPIs)

Revenue by SegmentAnalyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating how well the company diversifies its income streams.

$0.00$2.50B$5.00B$7.50B$10.00B$12.50BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Product revenue has shifted from steady to accelerating in H1‑2026, reflecting the Eliquis-led and broader growth‑portfolio strength that underpins management’s raised guidance; this makes product performance the primary driver of near‑term upside. “Other” has become a noticeably lumpier but slightly larger contributor since late‑2024, adding volatility rather than scale, while Alliance receipts are flat-to-declining, signaling limited partner upside. The stock’s path now hinges on sustaining Eliquis/growth product momentum and successful launches—legacy generic pressure and Opdivo softness remain the main downside risks.

Data provided by:The Fly

Bristol-Myers Squibb (BMY) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%60%BMY+43.08%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$128.63B
Dividend Yield
4.00%
Average Volume (3M)
10.96M
Price to Earnings (P/E)
13.9
Beta (1Y)
0.24
Revenue Growth
4.19%
EPS Growth
52.55%
Country
US
Employees
32,500
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

Bristol-Myers Squibb Business Overview & Revenue Model

Company Description

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hemato...

How the Company Makes Money

BMS makes money primarily by selling branded prescription drugs. Revenue is recognized from product sales to wholesalers, specialty distributors, hospitals, and other customers, with net sales reflecting typical industry deductions such as government...

Bristol-Myers Squibb Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:3.90%|Next Earnings Date:Feb 04, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Management reported 7% total revenue growth, 12% growth in the growth portfolio, strong performance from multiple key brands, raised full-year guidance, substantial cash generation, and several positive late-stage pipeline readouts. The principal challenges were the upcoming Eliquis loss of exclusivity, declines in parts of the legacy portfolio and Opdivo, execution issues for Cobenfy, uncertainty around the higher admilparant dose, and the Zolacel program pause following a fatal event. Highlights significantly outweighed the lowlights.

Positive Updates

Double-Digit Growth in Growth Portfolio
The growth portfolio delivered another quarter of double-digit growth, with sales increasing 12% in the third quarter to $7.7 billion, driven by a broad set of differentiated products.

Negative Updates

Opdivo Revenue Decline
Opdivo revenue decreased 6% year over year to $2.4 billion, primarily reflecting continued conversion to Qvantig in the U.S. and Europe.

Company Guidance

Bristol Myers Squibb increased its full year revenue guidance; its expected non GAAP EPS guidance range for 2026 is now $6.35 to $6.55, and excluding the third quarter acquired in process R&D charges and licensing income of $0.58 per share, the midpoint would have increased by approximately $0.15 per share. The company is maintaining its projections for gross margin, operating expenses, and tax rate, while slightly lowering the expense level on its other income and expense line; total legacy portfolio revenue decrease is now expected to be between 3% to 5%, while Eliquis full year revenue growth is expected to be 20% to 25%. For 2027, Eliquis is expected to have a $1.5 billion to $2 billion step down, and the strategic productivity initiative is on track to achieve $2 billion worth of efficiencies by the end of 27; the company also expects physicians to convert at least 30% to 40% of IV business to Qvantig, tracking towards the higher end of that range.

Bristol-Myers Squibb Financial Statement Overview

Summary

Solid current profitability and cash generation (TTM net margin ~18%, EBIT margin ~20%, strong historical FCF-to-net-income conversion), but the profile is held back by a leveraged balance sheet in the annual data and notable earnings volatility (2024 loss followed by a sharp rebound). Recent free cash flow growth turning negative also reduces confidence in near-term cash momentum.

Income Statement

74Positive

Balance Sheet

52Neutral

Cash Flow

71Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue50.03B48.20B48.30B45.01B46.16B46.38B
Gross Profit34.64B34.26B34.33B34.31B36.02B36.45B
EBITDA15.15B15.23B3.17B19.37B19.22B20.12B
Net Income9.24B7.05B-8.95B8.03B6.33B6.99B
Balance Sheet
Total Assets88.77B90.04B92.60B95.16B96.82B109.31B
Cash, Cash Equivalents and Short-Term Investments12.58B10.67B10.86B12.28B9.25B17.22B
Total Debt44.81B47.14B51.20B41.46B40.72B45.60B
Total Liabilities65.37B71.53B76.22B65.67B65.70B73.31B
Stockholders Equity23.40B18.47B16.34B29.43B31.06B35.95B
Cash Flow
Free Cash Flow9.29B12.85B13.94B12.65B11.95B15.23B
Operating Cash Flow10.65B14.16B15.19B13.86B13.07B16.21B
Investing Cash Flow-5.31B-4.13B-21.35B-2.29B-1.06B-538.00M
Financing Cash Flow-11.44B-10.35B5.13B-9.42B-16.96B-16.22B

Bristol-Myers Squibb Technical Analysis

Technical Analysis SentimentPositive
Last Price62.93

Price Trends

50DMA61.59Positive
100DMA61.90Positive
200DMA59.40Positive

Market Momentum

MACD0.47Negative
RSI53.79Neutral
STOCH37.58Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMY, the sentiment is Positive. The current price of 62.93 is above the 20-day moving average (MA) of 62.28, above the 50-day MA of 61.59, and above the 200-day MA of 59.40, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 53.79 is Neutral, neither overbought nor oversold. The STOCH value of 37.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BMY.

Bristol-Myers Squibb Risk Analysis

Bristol-Myers Squibb disclosed 23 risk factors in its most recent earnings report. Bristol-Myers Squibb reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.Expectations relating to environmental, social and governance considerations and related reporting obligations expose the Company to potential liabilities, increased costs, reputational harm, and other adverse effects on the Company's business.Q4, 2023

Bristol-Myers Squibb Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BMY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
LLYLLY81Outperform$1.35T46.5483.65%0.48%45.51%50.48%
AMGNAMGN75Outperform$250.07B26.6585.59%2.15%8.60%33.48%
NVSNVS72Outperform$295.59B31.0824.24%2.96%1.64%-28.72%
ABBVABBV71Outperform$520.65B50.56-202.43%2.35%10.68%338.08%
BMYBMY69Neutral$128.63B13.9443.88%4.00%4.19%52.55%
MRKMRK64Neutral$356.13B147.395.29%2.35%5.21%-86.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%20%40%60%BMYAMGNLLYMRKNVSABBVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BMY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BMYBristol-Myers Squibb Company62.9319.0943.55%
AMGNAmgen Inc462.32129.1638.77%
LLYEli Lilly And Company1431.67388.3837.23%
MRKMerck & Company144.4652.1256.45%
NVSNovartis AG160.2035.3328.30%
ABBVAbbvie294.5568.4130.25%

Bristol-Myers Squibb Corporate Events

Business Operations and StrategyFinancial Disclosures

Bristol Myers Squibb Raises 2026 Outlook on Strong Q3

Positive
Oct 29, 2026

On October 29, 2026, Bristol Myers Squibb reported third quarter 2026 results, with total revenues rising 7% year-on-year to $13.1 billion and U.S. sales up 9%, underpinned by a 12% increase to $7.7 billion in its Growth Portfolio. GAAP EPS came in a...

Business Operations and StrategyFinancial Disclosures

Bristol Myers Squibb Raises 2026 Revenue Outlook

Positive
Jul 30, 2026

On July 30, 2026, Bristol Myers Squibb reported second-quarter 2026 results, highlighting a 6% year-on-year increase in total revenues to $13.0 billion and a 15% rise in Growth Portfolio sales to $7.6 billion, driven by Opdivo Qvantig, Reblozyl, Camz...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026